The landscape of type 2 diabetes management is rapidly evolving, particularly with the expanding roles of GLP-1 and GIP/GLP-1 receptor agonists. This program provides a simplified, evidence-based approach to antihyperglycemic agent selection, empowering you to confidently navigate therapeutic choices. Delve into the latest data from key cardiometabolic outcome trials and translate this evidence into practical strategies for your daily practice. Learn to implement a shared decision-making process that aligns with patient priorities; from glycemic targets and weight loss to cardiovascular risk reduction, to optimize cardiometabolic outcomes and enhance patient care.
Sponsorship for this program was provided as an unrestricted educational grant from Eli Lilly Canada Inc.